Bekeredjian R, Katus H A, Kuecherer H F
Department of Cardiology, University of Heidelberg, Germany.
Ultraschall Med. 2006 Apr;27(2):134-40. doi: 10.1055/s-2005-858993.
The development of second generation ultrasound contrast agents has extended the diagnostic scope of ultrasound imaging. Due to their physical characteristics, a therapeutic application of such microbubble based contrast agents has been promoted. Recently, several groups have demonstrated that ultrasound targeted microbubble destruction (UTMD) may deliver drugs or gene therapy vectors to organs accessible by ultrasound, thus providing a new technique for non-invasive, organ specific delivery of bioactive substances. Most applications in this field have been tested in cardiac models, but other organs can be treated as well. This article will give an overview of the background of UTMD and its non-cardiac applications.
第二代超声造影剂的发展扩展了超声成像的诊断范围。由于其物理特性,基于微泡的此类造影剂的治疗应用得到了推动。最近,多个研究小组证明,超声靶向微泡破坏(UTMD)可将药物或基因治疗载体递送至超声可及的器官,从而提供了一种用于生物活性物质非侵入性、器官特异性递送的新技术。该领域的大多数应用已在心脏模型中进行了测试,但其他器官也可进行治疗。本文将概述UTMD的背景及其非心脏应用。